TGA / PMDA / NMPA · Asia-Pacific
intravenous — TGA / PMDA / NMPA regulatory status
intravenous regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 129 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 1001 | Phase 3 | Biotest Farmaceutica Ltda | 2024-513002-60-00 |
| 160701 | Phase 3 | Takeda | NCT00818662 |
| 161003 | Phase 3 | Takeda | NCT01524887 |
| 161202 | Phase 3 | Takeda | NCT01736579 |
| 170904 | Phase 3 | Takeda | NCT01218438 |
| 61186372NSC3001 | Phase 3 | Janssen-Cilag International N.V | 2023-506033-29-00 |
| 61186372NSC3002 | Phase 3 | Janssen-Cilag International N.V | 2023-506518-33-00 |
| 8951-CL-0301 | Phase 3 | Astellas Pharma | 2024-511365-11-00 |
| 8951-CL-0302 | Phase 3 | Astellas Pharma | 2024-511648-16-00 |
| 8951-CL-0305 | Phase 3 | Astellas Pharma | 2024-519773-19-00 |
| ALN-TTR02-011 | Phase 3 | Alnylam Netherlands | 2023-508364-29-00 |
| AV-299-23-301 | Phase 3 | Anaxis Pharma | 2023-505606-42-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12371333 | Purification of clinoptilolite | US |
| 12343350 | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF) | US |
| 2025002606 | Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA | US |
| 2023302008 | METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE | US |
| 11629060 | Purification of clinoptilolite | US |
| 11596610 | Compositions in support of health and mental accuity | US |
| 11583540 | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF) | US |
| 11197869 | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF) | US |
| 11202104918P | THERAPY FOR TREATING CANCER WITH AN INTRATUMORAL AND/OR INTRAVENOUS ADMINISTRATION OF A RECOMBINANT MVA ENCODING 4-1BBL (CD137L) AND/OR CD40L | SG |
| 10117937 | Highly branched alpha-D-glucans | US |
| 10010534 | Intravenous formulation and LC/MS/MS analysis method for GMC1 | US |
| 9675572 | Intravenous omega-3 fatty acid compositions and method of use | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of intravenous?
intravenous currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get intravenous regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to intravenous?
This spoke lists 129 published programs associated with intravenous in our pipeline index.